• Aliases: AMG 412; humanized anti-CD22 monoclonal antibody IgG1; monoclonal antibody LL2
    • A recombinant, humanized mAb directed against CD22, a cell surface glycoprotein present on mature B cells and on many types of malignant B cells
    • Currently in phase 1/2 clinical trials for hematologic malignancies
    • Pending FDA approval for systemic lupus
    • Recommended phase 2 dose: A range of 360 to 480 mg/m2/week IV over 30 to 60 minutes for 4 weeks
    • Half-life: â™23 days
    • Side effects: Infusion-related side effects (chills, fevers, rigors), infections
    (Coleman et al., 2003; Leonard et al., 2003)
    Other topics in Targeted and Immunotherapy Agents